Stockscreener 앱 받기
17.11
1.00%
0.17
시간 외 거래:
17.09
-0.02
-0.12%
전일 마감가:
$16.94
열려 있는:
$17.13
하루 거래량:
354.09K
Relative Volume:
0.90
시가총액:
$6.11B
수익:
$5.21B
순이익/손실:
$-211.00M
주가수익비율:
-27.69
EPS:
-0.6179
순현금흐름:
$861.30K
1주 성능:
+1.48%
1개월 성능:
-4.94%
6개월 성능:
+3.76%
1년 성능:
+15.92%
1일 변동 폭
$16.80
$17.16
1주일 범위
$16.60
$17.29
52주 변동 폭
$13.77
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
명칭
Bausch Lomb Corp
전화
908-541-5456
주소
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, RMD, MDLN, ALC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
17.11 | 6.02B | 5.21B | -211.00M | 861.30K | -0.6179 |
ISRG
Intuitive Surgical Inc
|
391.95 | 138.47B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
176.80 | 50.07B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
218.89 | 32.02B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
35.61 | 30.44B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
63.76 | 31.16B | 10.63B | 819.00M | 1.59B | 1.6577 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | 개시 | Goldman | Neutral |
| 2025-05-02 | 재확인 | H.C. Wainwright | Buy |
| 2025-03-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-07-10 | 개시 | Raymond James | Outperform |
| 2024-05-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-12-12 | 개시 | Stifel | Hold |
| 2023-10-03 | 재개 | Evercore ISI | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-03-09 | 개시 | Needham | Hold |
| 2022-12-21 | 개시 | Barclays | Equal Weight |
| 2022-09-12 | 개시 | H.C. Wainwright | Buy |
| 2022-07-26 | 개시 | RBC Capital Mkts | Outperform |
| 2022-06-24 | 개시 | Evercore ISI | Outperform |
| 2022-06-06 | 개시 | Citigroup | Buy |
| 2022-05-31 | 개시 | Deutsche Bank | Hold |
| 2022-05-31 | 개시 | Goldman | Neutral |
| 2022-05-31 | 개시 | Guggenheim | Buy |
| 2022-05-31 | 개시 | JP Morgan | Neutral |
| 2022-05-31 | 개시 | Jefferies | Buy |
| 2022-05-31 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 개시 | Wells Fargo | Overweight |
| 2022-05-11 | 개시 | Cowen | Outperform |
모두보기
Bausch Lomb Corp 주식(BLCO)의 최신 뉴스
Bausch + Lomb (TSX:BLCO): What Does SeeLyra Approval Mean? - Kalkine Media
Responsive Playbooks and the BLCO Inflection - Stock Traders Daily
Former Bausch & Lomb Director Karen Ling Files Form 144 to Sell 4,500 Shares - Kalkine Media
A former director plans to sell 4,500 Bausch & Lomb (BLCO) shares from stock vesting. - Stock Titan
Bausch Lomb (TSX:BLCO): Eye Health Growth In Healthcare - Kalkine Media
Bausch + Lomb stock reports 9.1 percent revenue growth - AD HOC NEWS
Veterinary Ophthalmology Equipment Market by Product, Animal Type, Application, End User, Region Report Forecasts Market to Reach USD 0.83 Billion by 2031, Growing at a 7.7% CAGR - GlobeNewswire Inc.
Bausch & Lomb Corp (BLCO) Stock Up 3.1% and Still Undervalued -- GF Score: 77/100 - GuruFocus
Bausch + Lomb Corporation (BLCO) Stock Analysis: Potential 12.99% Upside Beckons Investors in the Healthcare Sector - DirectorsTalk Interviews
Bausch + Lomb stock holds steady as investors watch latest fundamentals - AD HOC NEWS
Bausch + Lomb Q2 2026 Earnings: EPS Edges Past Estimates as Stock Slips SlightlyEarnings Forecast Report - careplusvn.com
Robinson Pharma, Inc. Receives "Above and Beyond" Supplier Award from Bausch + Lomb for September 2026 - Yahoo Finance
US FDA Warning To Bausch + Lomb Suggests Potential For Recall, Production Interruption - insights.citeline.com
Bausch + Lomb's SeeLyra femtosecond laser earns European CE mark - Ophthalmology Times
BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser - Eastern Progress
BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure - Stocktwits
Bausch + Lomb receives CE Mark for SeeLyra laser - grafa.com
Stocks in play: Bausch + Lomb Corporation - The Globe and Mail
Bausch + Lomb receives CE Mark for SeeLyra femtosecond laser - investing.com
Bausch + Lomb receives CE Mark for SeeLyra femtosecond laser By Investing.com - Investing.com India
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser - Eagle-Tribune
Bausch + Lomb Appoints Rob Nadler as SVP, Business Development and Corporate Strategy - VisionMonday.com
The Technical Signals Behind (BLCO) That Institutions Follow - Stock Traders Daily
Leerink Partners Initiates Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Announces Target Price $24 - Moomoo
(BLCO) Advanced Trading Insights (BLCO:CA) - Stock Traders Daily
Bausch + Lomb Corporation (BLCO) Investor Outlook: Eyeing a 3.24% Upside Amid Diverse Global Operations - DirectorsTalk Interviews
Bausch + Lomb stock rises on survey-driven dry eye focus - AD HOC NEWS
Why Bausch + Lomb Corp stock is gaining today - Wealth Awesome
Bausch + Lomb study shows enVista Aspire lenses improve vision By Investing.com - Investing.com Canada
Bausch + Lomb study shows enVista Aspire lenses improve vision - investing.com
Every patient in the study reached mid-range vision after cataract surgery. - Stock Titan
Does Advancing First-in-Class Dry Eye and Pain Drugs Change The Bull Case For Bausch + Lomb (BLCO)? - simplywall.st
Is Bausch + Lomb (TSX:BLCO) Strengthening Eye Care Leadership? - Kalkine Media
Bausch + Lomb Corporation - Menafn
Bausch + Lomb Survey Finds 14% Link Dry Eye to Menopause | BLCO Stock News - Stock Titan
Bausch + Lomb Corporation (BLCO) Stock Report: Analyzing a 9.10% Revenue Growth in the Healthcare Sector - DirectorsTalk Interviews
Bausch + Lomb (BLCO) Stock Trades Below Fair Value As Caution Lingers - Yahoo Finance
H.C. Wainwright Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Bausch + Lomb Advances Two First-in-Class Eye Health Therapies - Prime Publishers, Inc.
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal - TradingView
Trading (BLCO) With Integrated Risk Controls (BLCO:CA) - Stock Traders Daily
Bausch + Lomb: The Market Is Pricing The Balance Sheet, Not The Eye-Care Engine - Seeking Alpha
Did Bausch + Lomb’s (BLCO) Board Overhaul Amid Weak Returns Just Shift Its Investment Narrative? - simplywall.st
Bausch + Lomb Corporation (BLCO) Stock Analysis: Eyeing a 9.24% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Bausch + Lomb Director Robert J. Chersi Granted 11,776 RSUs Under 2022 Incentive Plan - Kalkine Media
Bausch & Lomb (BLCO) director Barbara Trebbi receives 11,776-share RSU award - Stock Titan
Bausch & Lomb (BLCO) files Form 3 for new director Barbara Trebbi - Stock Titan
Bausch & Lomb (BLCO) director awarded 11,776 RSU-based common shares - Stock Titan
Bausch & Lomb (BLCO) director receives 11,776 RSU equity grant as compensation - Stock Titan
Bausch & Lomb Corp (BLCO) adds director Robert J. Chersi in Form 3 filing - Stock Titan
Bausch Lomb Corp (BLCO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.06%
0.87%
자본화:
|
볼륨(24시간):